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CEAF

:   cost‐effectiveness frontier

CHB

:   chronic hepatitis B

CI
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FN

:   false negative

FP

:   false positive

HBV

:   hepatitis B virus

HCC

:   hepatocellular carcinoma

ICER

:   incremental cost‐effectiveness ratio

NITs

:   noninvasive tests

QUADAS

:   Quality Assessment of Diagnostic Accuracy Studies

QUALYs

:   quality‐adjusted‐life‐years

TN

:   true negative
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:   true positive

Introduction {#jvh12469-sec-0002}
============

It is estimated that 350--400 million people worldwide are hepatitis B virus (HBV) carriers [1](#jvh12469-bib-0001){ref-type="ref"} and are therefore at risk for progressive liver disease leading to cirrhosis and hepatocellular cancer (HCC) with associated increased morbidity and mortality. To prevent such progression, antiviral treatment is administered to patients who fulfil certain criteria, based on a combined assessment of viral load, transaminase level and/or liver fibrosis. Indeed, EASL guidelines state that patients should be considered for antiviral treatment when they have HBV DNA levels \>2000 IU/mL, serum ALT levels above the upper limit of normal and severity of liver disease as assessed by liver biopsy (or noninvasive markers once validated in HBV‐infected patients) showing at least moderate necroinflammation and/or fibrosis [1](#jvh12469-bib-0001){ref-type="ref"}.

The current reference standard for assessing liver fibrosis is the histological evaluation of liver biopsy with scoring systems such as METAVIR or Ishak [2](#jvh12469-bib-0002){ref-type="ref"}, [3](#jvh12469-bib-0003){ref-type="ref"}. However, liver biopsy is an invasive and costly procedure, inconvenient to patients and associated with a small risk of significant bleeding (1.1--1.6%) [4](#jvh12469-bib-0004){ref-type="ref"}, [5](#jvh12469-bib-0005){ref-type="ref"}. Alternatives to liver biopsy include noninvasive fibrosis tests (NITs), which can be broadly divided into three categories: simple/indirect serum markers, direct or patented serum markers and imaging modalities. Simple serum NITs, such as APRI and FIB4, consist of readily available indirect markers of fibrosis such as ALT, AST and platelet count, and are associated with lower costs. Other serum tests such as Fibrotest are patented and must be performed in laboratories that meet certain quality standards, and are therefore more expensive and less available. Transient elastography, which is performed with Fibroscan, is the most widely used imaging modality and measures liver stiffness based on ultrasound principles using dedicated equipment. Simple NITS, such as APRI and FIB‐4 have two cut‐offs for diagnosing specific fibrosis stages, as the use of a single cut‐off would result in suboptimal sensitivity and specificity. These are a high cut‐off with high specificity or a low cut‐off with high sensitivity. A combined cut‐off uses the low cut‐off to rule out the presence of a particular stage of fibrosis, and the high cut‐off to confirm that the patient has a particular stage of fibrosis [16](#jvh12469-bib-0016){ref-type="ref"}. However, a number of patients fall in the indeterminate range of test results (i.e. their score is between the low and the high cut‐off) and need alternative testing or future re‐testing.

Noninvasive tests may offer cost‐effective alternatives to liver biopsy. However, currently there are no studies that assess their cost‐effectiveness in patients with chronic hepatitis B (CHB) within a health care setting. We assessed the diagnostic accuracy and cost‐effectiveness of NITs in patients with CHB, who would normally undergo liver biopsy to inform treatment decisions.

Methods {#jvh12469-sec-0003}
=======

Systematic review {#jvh12469-sec-0004}
-----------------

We performed a systematic review and meta‐analysis to determine the diagnostic accuracy of NITs compared to liver biopsy in adult patients with CHB. This study was part of a larger project funded by the UK National Institute of Health Research (NIHR) Health Technology Assessment Programme [6](#jvh12469-bib-0006){ref-type="ref"} that determined the cost‐effectiveness of noninvasive tests in patients with CHB, hepatitis C [7](#jvh12469-bib-0007){ref-type="ref"}, alcoholic liver disease and nonalcoholic fatty liver disease.

Study selection and data extraction {#jvh12469-sec-0005}
-----------------------------------

We included full papers and abstracts which provided the data necessary to determine the number of true positive (TP), true negative (TN), false positive (FP) and false negative (FN) results of the NITs for ≥F2 using liver biopsy as the reference standard, irrespective of language or publication status and whether the data were collected prospectively or retrospectively. We excluded studies which reported on fewer than 10 patients and when the maximum interval between liver biopsy and the NITs was \>6 months.

The search strategy, data extraction and analysis were performed as previously described [7](#jvh12469-bib-0007){ref-type="ref"} and are detailed in the Appendix S1.

The quality of the included studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS)‐2 assessment tool [8](#jvh12469-bib-0008){ref-type="ref"}. The criteria used for QUADAS‐2 assessment are shown in the Appendix S1.

Economic model {#jvh12469-sec-0006}
--------------

### Approach to analysis {#jvh12469-sec-0007}

The systematic review identified a total of 25 NITs; however the quantity and quality of the evidence varied between the NITs (Table [1](#jvh12469-tbl-0001){ref-type="table-wrap"}). The base case cost‐effectiveness analysis compared those NITs for which data on sensitivity and specificity were considered robust, defined as whether the bivariate model used in the meta‐analysis converged (*n* = 5): APRI (high cut‐off and low cut‐off); Fibroscan; Fibrotest; and FIB4 (low cut‐off). We compared the cost‐effectiveness of NITs based on four different antiviral treatment scenarios: (i) treat all patients without prior fibrosis evaluation, (ii) treat no patients and no fibrosis evaluation to inform this decision (watchful waiting), (iii) biopsy all patients and treat those with a METAVIR fibrosis stage ≥F2, (iv) test with NIT and treat patients with a METAVIR fibrosis stage ≥F2.

###### 

Diagnostic accuracy of noninvasive tests for detection of ≥F2 in patients with chronic hepatitis B

  Test                                   Number of studies   Cut‐off      Summary sensitivity   95% CI       Summary specificity   95% CI       Statistics
  -------------------------------------- ------------------- ------------ --------------------- ------------ --------------------- ------------ -------------------------------------------------------------------------------------------------
  Indirect non‐invasive serum tests                                                                                                             
  APGA                                   1                   6.7          0.17                  0.10--0.27   0.98                  0.95--0.99   Single study
  APRI (low cut‐off)                     8                   0.4--0.6     0.80                  0.68--0.88   0.65                  0.52--0.77   Bivariate random‐effects model with correlation between sensitivity and specificity
  APRI (high cut‐off)                    6                   1.5          0.37                  0.22--0.55   0.93                  0.85--0.97   Bivariate random‐effects model with correlation between sensitivity and specificity
  Age_Platelet index                     1                   3            0.68                  0.61--0.74   0.62                  0.57--0.67   Single study
  AST_ALT_ratio                          1                   0.67         0.57                  0.51--0.64   0.59                  0.54--0.63   Single study
  FIB‐4 (low cut‐off)                    4                   1.1--1.7     0.68                  0.60--0.75   0.73                  0.67--0.79   Bivariate random‐effects model with correlation between sensitivity and specificity
  FIB‐4 (high cut‐off)                   1                   3.25         0.58                  0.04--0.17   0.99                  0.96--1.00   Single study
  Forns index (low cut‐off)              1                   4.2          0.58                  0.47--0.68   0.77                  0.61--0.88   Single study
  Forns index (high cut‐off)             1                   6.9          0.15                  0.08--0.24   1.00                  0.90--1.00   Single study
  GUCI                                   1                   0.2          0.67                  0.55--0.76   0.97                  0.85--0.99   Single study
  Hui index                              1                   0.15         0.50                  0.39--0.61   0.91                  0.78--0.97   Single study
  PAPAS                                  1                   1.67         0.73                  0.62--0.81   0.78                  0.71--0.84   Single study
  Direct serum noninvasive serum tests                                                                                                          
  Hyaluronic acid                        1                   185.3        0.84                  0.73--0.91   0.83                  0.66--0.93   Single study
  Hepascore                              1                   0.5          0.79                  0.68--0.86   0.74                  0.65--0.81   Single study
  Commercial noninvasive serum tests                                                                                                            
  Fibrotest                              6                   0.40--0.48   0.66                  0.57--0.75   0.80                  0.72--0.86   Bivariate random‐effects model with correlation between sensitivity and specificity
  Imaging modalities                                                                                                                            
  ARFI                                   1                   1.33         0.71                  0.59--0.80   0.67                  0.30--0.90   Single study
  Fibroscan                              13                  6.3--8.9     0.71                  0.62--0.78   0.84                  0.74--0.91   Bivariate random‐effects model with correlation between sensitivity and specificity
  CEUS                                   3                   --           0.88                  0.07--1      0.73                  0.11--0.98   Random‐effects model for sensitivity and specificity without correlation
  DWMRI                                  5                   --           0.78                  0.63--0.88   0.78                  0.51--0.93   Random‐effects model for sensitivity and specificity without correlation
  MRE                                    3                                0.94                  0.13--1      0.92                  0.72--0.98   Random‐effects model for sensitivity and fixed‐effect model for specificity without correlation
  US                                     3                   --           0.35                  0.14--0.63   0.86                  0.59--0.96   Bivariate random‐effects model with correlation between sensitivity and specificity
  US_SAPI                                3                   --           0.74                  0.69--0.79   0.79                  0.72--0.85   Fixed‐effects model for sensitivity and specificity without correlation
  US_SAPI High cut‐off                   2                   --           0.61                  0.54--0.68   0.96                  0.9--0.98    Fixed‐effects model for sensitivity and specificity without correlation
  US_SAPI_F2low cut‐off                  2                   --           0.94                  0.9--0.97    0.39                  0.31--0.49   Fixed‐effects model for sensitivity and specificity without correlation

CI, confidence intervals; APGA, AST, Platelet count; GGT, A‐fetoprotein; APRI, AST‐to‐platelet ratio index; FIB‐4, Fibrosis‐4; GUCI, Goteborg University Cirrhosis Index; PAPAS, Age; ALP, a‐fetoprotein; AST, ARFI; acoustic radiation force impulse; CEUS, contrast enhanced ultrasound; DWMRI, diffusion‐weight magnetic resonance imaging; MRE, magnetic resonance elastography; US, ultrasound; US_SAPI, splenic artery pulsatility index determination by ultrasound.

John Wiley & Sons, Ltd

### Model structure {#jvh12469-sec-0008}

The analyses were based on a decision tree framework, combined with a Markov model to estimate the long‐term costs and outcomes associated with each potential test diagnosis: TP, FP, FN or TN and the 'treat all' and 'treat no one' testing strategies.

The Markov model estimated the health outcomes and costs for a hypothetical cohort of 1000 CHB patients with suspected fibrosis, who would usually present for liver biopsy. Separate Markov models were constructed for the HBeAg‐ positive and HBeAg‐negative patient cohorts to reflect differences in disease progression and patient characteristics. The structural assumptions underlying the state transition models applied to both groups of patients. Figure [1](#jvh12469-fig-0001){ref-type="fig"} provides a schematic illustration of the pathway. The cohort of 1000 CHB patients started the model in either the mild, moderate or cirrhotic health states (≤F4), depending on the outcome being modelled (TN, TP, FP, FN, treat all and treat no‐one). The distribution of the population among the different health states was based on the prevalence data from the systematic review. The Markov models were evaluated over a lifetime period with a cycle length of 1 year. Health outcomes were expressed as quality‐adjusted‐life‐years (QALYs), which combine data on life expectancy with data reflecting quality of life. All unit costs reported in the analysis for health states and liver biopsy, are priced for the year 2012 and were considered from the perspective of the UK National Health System (NHS). Costs and QALYs were discounted using a rate of 3.5% [9](#jvh12469-bib-0009){ref-type="ref"}. Cost‐effectiveness was assessed according to thresholds used by the UK National Institute for Health and Care Excellence, which include a threshold of £20 000, increasing up to around £30 000 when specific additional considerations are important [9](#jvh12469-bib-0009){ref-type="ref"}.

![Illustration of the Markov Model used for economic analysis. The disease stages reflect the METAVIR staging score for liver fibrosis and cirrhosis. The cohort represents people suspected of liver fibrosis who can enter the models in one of three disease stages; mild fibrosis (METAVIR stages F0--F1), moderate fibrosis (METAVIR stages F2--3) and compensated cirrhosis (METAVIR stage F4) with the proportions determined by the prevalence estimated from the results of the systematic review. Within the model, people can remain within any disease stage for longer than one cycle (length of cycle is set as 1 year) except for the liver transplant disease stage where patients can only progress to either a post‐liver transplant stage or death.](JVH-23-139-g001){#jvh12469-fig-0001}

The decision tree was populated with results from the Markov model, summary sensitivity and specificity estimates and average disease prevalence estimate (METAVIR ≥F2 extracted from the meta‐analysis), to estimate the cost‐effectiveness of all comparators.

### Input parameters {#jvh12469-sec-0009}

Current recommended treatment options for chronic CHB include indefinite treatment with nucleoside or nucleotide analogues or pegylated interferon alpha for a period of 12 months [1](#jvh12469-bib-0001){ref-type="ref"}. Treatment with antiviral agents, entecavir or tenofovir (50--50 split) was initiated in the model for a patient with positive (METAVIR ≥F2) diagnosis. Only patients in the moderate fibrosis, compensated cirrhosis or decompensated cirrhosis health states received treatment with antiviral agents. Patients in the HCC, liver transplant and post‐liver transplant health states received usual standard of care. Treatment effectiveness was sourced from a published meta‐analysis by Woo *et al*. [10](#jvh12469-bib-0010){ref-type="ref"}; treatment efficacy of the drugs (represented by relative risks in the model) are listed in Table [2](#jvh12469-tbl-0002){ref-type="table-wrap"}.

###### 

Input parameters for model

  Model inputs             Parameter value   Distribution   Source
  ------------------------ ----------------- -------------- ------------------------------------------------------------
  Cohort characteristics                                    
  HBeAg‐positive                                            
  Starting age             31 years                         
  Gender % male            70%                              Shepherd *et al*. [25](#jvh12469-bib-0025){ref-type="ref"}
  HBeAg‐negative                                            
  Starting age             40 years                         
  Gender % male            90%                              

  Natural history data (Transition probabilities)                                                                                         
  ---------------------------------------------------------- ----------------- ---------------------------------------------------------- --
  Mild‐moderate fibrosis                                     0.025             Dirichlet                                                  
  Moderate fibrosis‐compensated Cirrhosis (HBeAg‐positive)   0.037             Wright *et al*. [12](#jvh12469-bib-0012){ref-type="ref"}   
  Moderate Fibrosis‐compensated cirrhosis (HBeAg‐negative)   0.09                                                                         
  Compensated cirrhosis‐decompensated cirrhosis              0.05                                                                         
  Moderate Fibrosis‐Hepatocellular Cancer (HCC)              0.048             Dakin *et al*. [11](#jvh12469-bib-0011){ref-type="ref"}    
  Cirrhosis to HCC                                           0.024                                                                        
  Decompensated cirrhosis/HCC‐ liver transplant              0.016                                                                        
  Decompensated cirrhosis‐death                              0.30                                                                         
  Liver transplant‐death                                     0.21                                                                         
  Post Liver transplant‐death                                0.057                                                                        
  Excess mortality                                                                                                                        
  Moderate fibrosis                                          0.035                                                                        
  Compensated cirrhosis                                      0.051                                                                        
  HCC                                                        0.56                                                                         
  Treatment dosage                                                                                                                        
  Peginterferon alfa‐2a                                      180 mg (weekly)                                                              
  Entecavir                                                  500 mg (daily)    British National Formulary 64                              
  Tenofovir                                                  245 mg (daily)                                                               

  Treatment efficacy (Relative risks)                                     
  ------------------------------------- ------ ------ ------ ------------ -------------------------------------------------------
  HBeAg‐positive                                                          
  Entecavir                             0.56   0.12   0.94   Gamma        
  Tenofovir                             0.53   0.06   0.95   Gamma        Woo *et al*. [10](#jvh12469-bib-0010){ref-type="ref"}
  Peginterferon alfa‐2a                 0.52   0.06   0.95   Lognormal    
  HBeAg‐negative                                                          
  Entecavir                             0.64   0.01   1.00   Gamma        
  Tenofovir                             0.65   0.01   1.00   Gamma        Woo *et al*. [10](#jvh12469-bib-0010){ref-type="ref"}
  Peginterferon alfa‐2a                 0.52   0.06   0.95   Log Normal   

  Health state costs                                                    
  ------------------------------------------ -------- --------- ------- -------------------------------------------------------------
  Mild fibrosis                              185      36.39     Gamma   Wright *et al*. [12](#jvh12469-bib-0012){ref-type="ref"}
  Moderate fibrosis                          986      101.69            
  Compensated cirrhosis                      1521     309.05            
  Decompensated cirrhosis                    36 194   9967.19   Gamma   Longworth *et al*. [14](#jvh12469-bib-0014){ref-type="ref"}
  Hepatocellular cancer                      36 194   9967.19           
  Liver transplant                           64 122   5584.70           
  Post‐liver transplant                      16 321   7932.51           
  Utilities                                                             
  Mild fibrosis                              0.77     0.035             Wright *et al*. [12](#jvh12469-bib-0012){ref-type="ref"}
  Moderate fibrosis                          0.66     0.0.18    Gamma   
  Compensated cirrhosis                      0.55     0.032             
  Decompensated cirrhosis                    0.57     0.076     Gamma   Longworth *et al*. [14](#jvh12469-bib-0014){ref-type="ref"}
  Hepatocellular cancer                      0.57     0.076             
  Liver transplant                           0.55     0.016             
  Post Liver transplant                      0.78     0.064             
  Mild Fibrosis (during treatment)           0.65     0.035     Gamma   Wright *et al*. [12](#jvh12469-bib-0012){ref-type="ref"}
  Moderate fibrosis (during treatment)       0.55     0.018             
  Compensated cirrhosis (during treatment)   0.45     0.040             
  Disutility following liver biopsy          0.2                        Assumed

  Treatment costs         Annual Cost (UK £2012)   
  ----------------------- ------------------------ -------------------------------
  Peginterferon alfa‐2a   6469                     
  Entecavir               4420                     British National Formulary 64
  Tenofovir               2926                     

John Wiley & Sons, Ltd

Treatment with peginterferon alfa‐2a was given for a 1 year period to 10% of those who tested negative to reflect a proportion of patients who may not have fibrosis but would receive treatment for necroinflammation [1](#jvh12469-bib-0001){ref-type="ref"}. We assumed that 30% of these TN patients who received treatment for 1 year would have a successful response to treatment and would no longer progress to more advanced disease stages. The remaining 90% who initially tested negative and those who had an unsuccessful response to peginterferon alfa‐2a treatment underwent a 'watchful waiting' process which incorporated a re‐test with an NIT every 2 years. If patients in the model had progressed to a ≥F2 health state at the time of re‐test, they received immediate treatment with antivirals (entecavir and tenofovir). We tested this assumption in a sensitivity analysis.

The rate of disease progression in the Markov model was sourced from a published cost‐effectiveness study by Dakin *et al*. [11](#jvh12469-bib-0011){ref-type="ref"}; however, this study did not report separate transition probability data for the precirrhotic health states (mild and moderate fibrosis). In the absence of transition probability data for the mild and moderate health states, we used data from a study of patients with mild chronic hepatitis C [12](#jvh12469-bib-0012){ref-type="ref"}. We assumed that the progression of early fibrosis would not differ significantly in patients with HCV and HBV.

We sourced health state costs and health‐related utility estimates, based on patients' self‐reported health status using the EQ‐5D questionnaire [13](#jvh12469-bib-0013){ref-type="ref"}, for the earlier disease stages (≤F4) from the study of patients with mild hepatitis C [12](#jvh12469-bib-0012){ref-type="ref"}. We assumed that the resource use identified and collected for this study (inpatient, outpatient and procedures, excluding medication costs) would be similar for patients with HCV and HBV; additionally this was the only study which estimated separate utilities for the mild and moderate health states (using EQ‐5D). We sourced costs and utilities for later disease stages (\>F4) from a cost‐effectiveness study of liver transplantation [14](#jvh12469-bib-0014){ref-type="ref"}, for which resource‐use and EQ‐5D data were available for a subgroup of patients with CHB. As we used two different sources of data, we conducted a sensitivity analysis using different utility values and health state costs for the later disease stages.

Cohort characteristics, mortality data, and treatment costs were sourced from published literature and routine national UK sources. Input parameters and sources are listed in Table [2](#jvh12469-tbl-0002){ref-type="table-wrap"}. Costs for the NITs and liver biopsy are listed in the Appendix S1.

### Analysis and uncertainty {#jvh12469-sec-0010}

We conducted an incremental analysis to identify the cost‐effective testing strategy. We ruled out tests strategies which were more costly and less effective 'dominated'. We then estimated Incremental Cost‐Effectiveness Ratios (ICER), for the remaining NITs, where they were compared to the next best alternative, calculated using the formula: $${ICER}\; = \;{\lbrack(}C_{1} - C_{0}{)/{(E_{1} - E_{0})}\rbrack},$$

where *C* ~1~ = lifetime cost of strategy 1; *C* ~0~ = lifetime cost of (the next best) strategy; *E* ~1~ = QALYs from strategy 1 and *E* ~0~ = QALYs from (the next best) strategy.

Test strategies with an ICER greater than that of a more effective intervention (extendedly dominated) were also ruled out and the remaining tests were then compared to identify the NIT with the highest ICER given a £20 000 per QALY threshold.

A probabilistic sensitivity analysis was run to estimate uncertainty in the mean results. We constructed the cost‐effectiveness frontier (CEAF), which plots the uncertainty associated with the optimal option (test with highest expected net benefit), for different values of the cost‐effectiveness threshold (threshold value range varied from £0 to £60 000) [15](#jvh12469-bib-0015){ref-type="ref"}.

Secondary analyses {#jvh12469-sec-0011}
------------------

We conducted a secondary analysis where we evaluated the sequential use of NITs (see appendix for sequential testing strategies).

We also carried out an analysis where we evaluated all identified NITs (*n* = 25), regardless of their robustness (robustness was defined as to whether the bivariate model converged for meta‐analysis).

Sensitivity analysis {#jvh12469-sec-0012}
--------------------

A number of one way sensitivity analyses were undertaken to vary some of the input parameters in the model, including changes to utility values, health state costs, average disease prevalence, assumption of treatment benefit for FP patients (mild health state F0‐1) and the re‐test assumption of perfect sensitivity and specificity.

Results {#jvh12469-sec-0013}
=======

Systematic review {#jvh12469-sec-0014}
-----------------

The selection flow chart for studies is shown in the Appendix S1. Data on patients with CHB were extracted from 52 studies that evaluated 25 different NITs. NIT cut‐offs for the diagnosis of specific histological stages were not always predetermined, and consequently varied. We opted not to perform a separate meta‐analysis for each stage‐specific cut‐off of a NIT, but to group together cut‐offs if the range was reasonable. Therefore, when a range of cut‐offs is mentioned in the results tables, the reported sensitivities and specificities are probably overestimated.

The summary sensitivities and specificities for each test are presented in Table [1](#jvh12469-tbl-0001){ref-type="table-wrap"}. The average prevalence of METAVIR score ≥F2 in the included studies was 54%. All but one study had a high risk of bias as assessed by the QUADAS‐2 tool (Appendix S1) therefore our results should be interpreted with caution. Strikingly, the cut‐offs of the NITs were predefined in 11/52 (21%) studies, while liver biopsy was of adequate quality (≥6 portal tracts and ≥15 mm) in 12/52 (23%) studies.

Economic modelling {#jvh12469-sec-0015}
------------------

### HBeAg‐negative chronic hepatitis B {#jvh12469-sec-0016}

The most effective strategy to employ is 'treat all without prior diagnostic testing', which had an ICER of £28 137. This would only be considered cost‐effective if the £30 000 upper bound of the UK cost‐effectiveness threshold range is considered acceptable; if not, a strategy of 'treat no one' would be the most cost‐effective. All other testing strategies are dominated by the 'treat all' strategy, as they are more costly and less effective. Table [3](#jvh12469-tbl-0003){ref-type="table-wrap"} displays results of the base case analysis.

###### 

HBeAg --negative base case analysis

  Testing option                      Cost £   QALYs   Incremental cost £   Incremental QALY   ICER £
  ----------------------------------- -------- ------- -------------------- ------------------ ----------------------
  Treat no one (no diagnostic test)   35 579   8.83    --                   --                 --
  Liver biopsy                        70 274   9.64    --                   --                 Dominated
  APRI (high cut off)                 69 429   9.71    --                   --                 Extendedly Dominated
  Fibroscan                           72 986   9.93    --                   --                 Extendedly Dominated
  Fibrotest                           73 857   9.94    --                   --                 Extendedly Dominated
  FIB 4 (low cut off)                 75 702   10.01   --                   --                 Extendedly Dominated
  APRI (low cut off)                  77 981   10.13   --                   --                 Extendedly Dominated
  Treat all (no diagnostic test)      96 525   10.92   58 947               2.09               28 137

John Wiley & Sons, Ltd

The CEAF (Appendix S2) for the HBeAg‐negative model shows that the probability of 'treat all' being on average the most cost‐effective testing option given a cost‐effectiveness threshold value of £30 000, is 39%.

### HBeAg‐positive chronic hepatitis B {#jvh12469-sec-0017}

For HBeAg‐positive patients at a cost‐effectiveness threshold of £30 000: the cost effective option to use when all tests were compared was Fibroscan, with an ICER of £23 345 (Table [4](#jvh12469-tbl-0004){ref-type="table-wrap"}). However, the CEAF (Figure Appendix) for the HBeAg‐positive model shows that the probability of Fibroscan being on average the most cost‐effective testing option given a cost‐effectiveness threshold value of £30 000 is low at 21%.

###### 

HBeAg --positive base case analysis

  Testing option                      Cost £    QALYs   Incremental cost £   Incremental QALY   ICER £
  ----------------------------------- --------- ------- -------------------- ------------------ ----------------------
  Treat no one (no diagnostic test)   37 831    9.64    --                   --                 --
  Liver biopsy                        75 957    11.41   --                   --                 Dominated
  APRI (high cut off)                 75 210    11.45   37 380               1.81               20 673
  Fibroscan                           79 000    11.61   3 790                0.16               23 345
  Fibrotest                           79 462    11.62   --                   --                 Extendedly Dominated
  FIB 4 (low cut off)                 81 382    11.67   --                   --                 Extendedly Dominated
  APRI (low cut off)                  83 788    11.75   --                   --                 Extendedly Dominated
  Treat all (no diagnostic test)      101 484   12.18   22 484               0.57               39 474

John Wiley & Sons, Ltd

A testing strategy 'treat all' without prior diagnostic testing provided a higher health gain (QALY) than Fibroscan, however, this option had an ICER of £39 747 which would not be acceptable given a £20 000--30 000 cost‐effectiveness threshold.

Secondary analyses {#jvh12469-sec-0018}
------------------

A secondary analysis where we evaluated the use of more than one NIT found that 'treat all' without prior diagnostic testing remained the most cost‐effective option for the HBeAg‐negative population with an ICER of £28 138, whereas for the HBeAg‐positive population, using APRI (low cut‐off) followed by Fibroscan using the second sequential testing strategy (appendix) was the most cost‐effective testing strategy with an ICER of £23 901 (see Appendix S1).

An analysis evaluating all of the NITs identified during the systematic review (irrespective of robustness) found similar results for the HBeAg‐negative population as the base case analysis (Treat all with an ICER of £28 137). However, for the HBeAg‐positive population, Magnetic Resonance Elastography (MRE) was the most cost‐effective option with an ICER of £23 468. This analysis found that several NITs had similar outcomes (cost and QALYs) (See Appendix S1 for incremental analysis tables).

Sensitivity analysis results {#jvh12469-sec-0019}
----------------------------

### HBeAg‐negative {#jvh12469-sec-0020}

The base results remained robust to the majority of sensitivity analyses; those they were sensitive to are detailed below.

Using the starting age and gender split used in the HBeAg‐positive model changed the results for the HBeAg‐negative population so that Fibroscan became the most cost‐effective testing option with an ICER of £25 575.

Amending the ≥F2 prevalence used in the model (54%) also changed the base results; when using a prevalence of 43% (lower quartile), the no testing and no treatment option was the most cost‐effective testing strategy (treat all testing strategy had an ICER of £30 413). When the maximum prevalence of 92% was used, Fibroscan was the most cost‐effective test with an ICER of £21 853.

We also tested the assumption that not all patients were diagnosed correctly at re‐test (watchful waiting strategy for patients who initially test negative) by using the sensitivity and specificity estimates of three commonly used tests \[APRI (low cut‐off), Fibrotest, and Fibroscan\]. With this analysis, Fibroscan became the most cost‐effective test when the sensitivity and specificity of Fibrotest or Fibroscan were used (ICERs of £27 584 and £27 088 respectively). There was no change to the base case results when the sensitivity and specificity for APRI (low cut‐off) was used for the re‐test.

In the base case all patients who tested positive (≥F2) received treatment with antiviral agents. When we assumed that patients in a mild health state (F0‐1), who were incorrectly diagnosed as having more advanced fibrosis (FP patients) would receive no benefit from treatment, the results changed so that 'treat no one' became the most cost‐effective option (the ICER for treat all increased to £35 081).

### HBeAg‐positive {#jvh12469-sec-0021}

The results were robust to the majority of sensitivity analyses, apart from the analyses detailed below.

We carried out four analyses where we amended the prevalence of ≥F2 used in the model. Amending the prevalence from 54% to 43% (lower quartile) changed the most cost‐effective test to APRI (high cut‐off) with an ICER of £19 989. When changing the prevalence to 65% (third quartile), the most cost‐effective testing option became 'treat all' irrespective of fibrosis stage with an ICER of £24 615. When using the maximum prevalence of 92%, APRI (high cut‐off) became the most cost‐effective test with an ICER of £18 186. Using the minimum ≥F2 prevalence (27%) also changed the most cost‐effective test to APRI (high cut‐off) with an ICER of £19 464.

When we assumed that patients in a mild health state, who were incorrectly diagnosed as having advanced fibrosis (FP patients), would receive no benefit from treatment, the most cost effective test was APRI (high cut‐off) with an ICER of £21 122.

The results changed when we tested the assumption that all persons were diagnosed correctly when a re‐test was performed (watchful waiting); APRI (low cut‐off) became the most cost‐effective test when the sensitivity and specificity of APRI (low cut‐off) or Fibrotest were used (ICERs of £24 651 and 29 644 respectively). There was no change to the base case results when the sensitivity and specificity for Fibroscan was used for the re‐test.

Discussion {#jvh12469-sec-0022}
==========

We compared five NITs with each other, liver biopsy and a 'treat all' and 'treat no one' approach for informing treatment decisions in chronic HBV patients. The overall results differed for the HBeAg‐positive and HBeAg‐negative patients.

In the HBeAg‐negative population, treating all patients based on viral load and ALT irrespective of the degree of fibrosis offered the largest QALY gain with an ICER of £28 317. There was some uncertainty in these results and the 'treat all strategy' had a 39% probability of having the highest net benefit, given a £30 000 cost‐effectiveness threshold. In the HBeAg‐positive population the most cost‐effective testing option was Fibroscan, however this NIT had a low (21%) probability of being the optimal testing option given a £30 000 cost‐effectiveness threshold.

Similar findings for treatment in patients with CHB have been reported in assessments conducted to inform national guidelines. For example, in the UK, entecavir for the treatment of HBeAg‐negative patients (assuming lifetime treatment duration) had an ICER of £27 124/QALY gained [17](#jvh12469-bib-0017){ref-type="ref"}, similar to our base case analysis result. The fact that antiviral treatment for CHB in the UK is cost‐effective at a £30 000 but not at a £20 000 cost‐effectiveness threshold reflects the high unit cost and lifetime duration of treatment [17](#jvh12469-bib-0017){ref-type="ref"}, [18](#jvh12469-bib-0018){ref-type="ref"}. Currently, a third of UK patients with HBV followed in liver centres are on antiviral treatment, however, only 18% of those treated are on recommended first‐line treatment [19](#jvh12469-bib-0019){ref-type="ref"}.

The difference between the HBeAg‐positive and negative results can be attributed to differences in baseline characteristics such as an older starting age within the model, higher male population, higher risk of developing cirrhosis, and the effectiveness of treatment in the HBeAg‐negative group.

Our data therefore suggest that liver biopsy is not cost‐effective for informing treatment decisions in patients with CHB in the UK and most probably in most developed countries, with the caveat regarding local costs, preferences and decision rules. A pragmatic cost‐effective approach therefore would be to treat HBeAg(−) patients based on high viral load and deranged ALT, irrespective of their fibrosis level. For HBeAg(+) patients, the most cost‐effective strategy is to perform a Fibroscan to inform treatment decisions in patients with high viral load and deranged ALT. This is a deviation from the current EASL guidelines, where liver biopsy is the preferred strategy irrespective of HBeAg status. It also simplifies treatment decisions in HBeAg(−) patients, who could be potentially seen in nurse‐led outpatient clinics.

Our meta‐analysis of NITs has been the most detailed and extensive to date, including all described serum tests and imaging modalities with no language restrictions and using state‐of‐the‐art statistical and reporting methods. A striking finding of our meta‐analysis was that the vast majority of studies had high risk of bias and failed in important methodological aspects, such as the absence of predetermined test cut‐offs and suboptimal quality of liver biopsy as the reference standard. Moreover, there was a paucity of sufficiently evaluated and validated NITs in patients with CHB. Indeed, there were adequate data for a reliable meta‐analysis in only four NITs, namely APRI, FIB4, Fibroscan and Fibrotest. A recent updated meta‐analysis on APRI and FIB‐4 showed similar diagnostic accuracy with the data presented in this paper [20](#jvh12469-bib-0020){ref-type="ref"}. The increasingly used Fibroscan does not have validated cut‐offs for specific fibrosis stages. Published cut‐offs are based on post hoc analyses and have not been prospectively validated in independent cohorts, therefore the reported diagnostic accuracy is most likely overestimated [21](#jvh12469-bib-0021){ref-type="ref"}. All tests performed significantly better in diagnosing cirrhosis than lesser fibrosis stages. Therefore, NITs in CHB need better quality studies and further validation, particularly for the diagnosis of moderate fibrosis.

Our economic modelling was performed from the perspective of an economy of a developed country and therefore its findings cannot be extrapolated to the developing world. This would require a separate analysis with different utilities and costs. A cost‐effectiveness analysis of antiviral treatment in middle‐income countries has shown that this is cost‐effective, however the use of NITs was not factored in the analysis [22](#jvh12469-bib-0022){ref-type="ref"}. However, the greatest burden of HBV infection is encountered in low‐income countries in Asia and the sub‐Saharan Africa. The World Health Organization has recently launched guidelines for treatment of people with CHB in such countries [23](#jvh12469-bib-0023){ref-type="ref"}. Treatment is recommended in patients with deranged ALT and viral load \>2000 IU/ml or those with evidence of cirrhosis, based on clinical finding or an APRI score of \>2. The choice of APRI was based on widespread availability rather than cost‐effectiveness analysis. Clearly, such countries would require subsidised costs of antiviral treatment, similar to the paradigm of HIV infection, for these guidelines to become applicable.

There are limitations to this analysis. Firstly, treatment decisions are far more complex than fibrosis evaluation in CHB, and depend on a global assessment that takes into account HBeAg status, viral load, transaminases, fibrosis and necroinflammation but also family history of HCC and family planning in females. Indeed, in some patients the decision to treat is straightforward without the need of a liver biopsy, and in others even a ≥F2 would not necessarily prompt treatment initiation. Therefore, this analysis is relevant only for patients who would require a liver biopsy to decide on treatment initiation, and not in unselected patients with CHB.

Secondly, the assumption that the re‐test carried out during the watchful waiting process correctly identified all patients who had progressed is a potential limitation; a sensitivity analysis incorporating the sensitivity and specificity estimates of three NITs found that the base case results did change for both populations, implying that this assumption may underestimate the ICER of treating all patients.

Thirdly, we did not include a health state specifically describing seroconversion in the model structure. This was for simplicity purposes as our outcome was treatment initiation rather than treatment effectiveness. Although some studies have shown that fibrosis and even cirrhosis can regress with antiviral therapy [24](#jvh12469-bib-0024){ref-type="ref"}, this is not factored into the model. This may underestimate the cost‐effectiveness of treatment.

In conclusion, to our knowledge, this analysis is the first to compare the cost‐effectiveness of a number of different NITs for use in patients with CHB. The current reference standard, liver biopsy was more costly and less effective than other tests in both the base case and sensitivity analyses. We identified that treating all patients (if eligible for treatment based on ALT and/or viral load) regardless of fibrosis level is the most cost‐effective strategy for HBeAg‐negative patients, whereas an NIT, Fibroscan is the most cost‐effective diagnostic strategy for HBeAg‐positive patients, although there is significant uncertainty around this result. These findings were robust to several sensitivity analyses.
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